CD40.HVac

About EnnoDC

EnnoDC is an innovative biotech developing first-in-class, dendritic cell-targeting immunotherapies. Its core technology, the 'DC engager' platform, creates bispecific antibodies that co-engage CD40 for dendritic cell activation and a disease-specific antigen for priming, effectively functioning as an in vivo 'Antibody Mediated Vaccine' (AMV). The company has validated its approach in early infectious disease trials and is now advancing a dynamic pipeline of five candidates, with a strategic presence in both Paris and Cambridge, Massachusetts. EnnoDC represents a compelling player in the next wave of immunotherapies aiming to combine the precision of checkpoint modulators with the durable memory of vaccines.

Therapeutic Areas